Amgen, Roche, Genentech deal

Amgen granted Roche’s Genentech unit exclusive, worldwide rights to develop and commercialize AMG 282, an antibody that inhibits the binding of IL-33 ( NF-HEV) to IL-1 receptor-like 1 ( IL1RL1; ST2)...